{"id":622199,"date":"2022-10-21T18:28:01","date_gmt":"2022-10-21T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=622199"},"modified":"2022-10-21T18:28:01","modified_gmt":"2022-10-21T18:28:01","slug":"metastatic-breast-cancer-pipeline-and-companies-analysis-report-2022-analysis-of-clinical-trials-landscape-therapies-route-of-administration-mechanism-of-action-and-developments-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-breast-cancer-pipeline-and-companies-analysis-report-2022-analysis-of-clinical-trials-landscape-therapies-route-of-administration-mechanism-of-action-and-developments-delveinsight_622199.html","title":{"rendered":"Metastatic Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1666325136.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1666325136.jpeg\" alt=\"Metastatic Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Metastatic Breast Cancer Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&#8216;Metastatic Breast Cancer Pipeline Insight 2022&#8217;<\/strong>&nbsp;report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Metastatic Breast Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Metastatic Breast Cancer Pipeline report depicts a robust space with<strong>&nbsp;120+&nbsp;<\/strong>active players working to develop&nbsp;<strong>120+&nbsp;<\/strong>pipeline therapies for Metastatic Breast Cancer treatment.&nbsp;<\/li>\n<li>Key Metastatic Breast Cancer pipeline therapies in various stages of development include&nbsp;<strong>Disitamab Vedotin, EndoTAG&reg;-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852,&nbsp;<\/strong>and others.<\/li>\n<li>The leading Metastatic Breast Cancer companies with various Metastatic Breast Cancer medications include&nbsp;<strong>RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd.,&nbsp; Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd.,&nbsp;<\/strong>and others are developing novel drug candidates to improve the&nbsp;Metastatic Breast Cancer treatment landscape.<\/li>\n<li>On May 04, 2022,&nbsp;<strong>Rhizen Pharmaceuticals AG<\/strong>&nbsp;announced the presentation of promising interim data from an ongoing Ph2 trial of&nbsp;<strong>Tenalisib<\/strong>&nbsp;in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022. Tenalisib was well tolerated and showed encouraging preliminary efficacy as a single agent in both primary and secondary resistant mBC; Data supports further development of Tenalisib in patients with HR+ and HER2- MBC.<\/li>\n<li>In April 2022,&nbsp;<strong>Alphamab Oncology<\/strong>&nbsp;announced that data from the phase II clinical study of the chemo-free regimen of&nbsp;<strong>KN026&nbsp;<\/strong>in combination with KN046 (KN026-203) were presented as an E-poster at the AACR Annual Meeting 2022 (AACR 2022). As of August 10, 2021, 24 patients with HER2-positive other solid tumors (non-breast cancer\/gastric cancer) who received &ge;1L prior systemic therapy were enrolled, 20 patients were evaluable for overall response:&nbsp;the ORR was 55.0%, the DCR was 85.0%, the 6-month PFS rate was 84.1%; Out of 11 evaluable CRC patients, the ORR and DCR was 45.5% and 90.9% respectively.<\/li>\n<li>In April 2022,&nbsp;<strong>Quantum Leap Healthcare Collaborative&trade;<\/strong>&nbsp;(Quantum Leap)&nbsp; and&nbsp;<strong>Ambrx Biopharma Inc<\/strong>., announced the selection of Ambrx&#8217;s antibody-drug conjugate (ADC)&nbsp;<strong>ARX788<\/strong>&nbsp;for a new investigational treatment arm in the I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting. Sponsored by Quantum Leap, the I-SPY 2.2 TRIAL is a continuation of the I-SPY 2 TRIAL that seeks to create personalized treatments by adapting therapies for each patient to optimize the clinical outcome.<\/li>\n<li>In March 2022,&nbsp;<strong>TYME Technologies, Inc.<\/strong>&nbsp;announced the availability of the poster abstract, &ldquo;SM-88, D\/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer,&rdquo; which was submitted by researchers from Georgetown University. The abstract was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.&nbsp; In September 2021, TYME Technologies, Inc. announced that the first patient had been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (&ldquo;HR+\/HER2-&ldquo;) breast cancer who previously received a CDK4\/6 inhibitor regimen being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals. (MedStar Health is Georgetown&rsquo;s academic clinical partner.)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/6889d82b1514fdd8c26e95bd99a1edf1.png\" alt=\"\" \/><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Request a sample and discover the recent breakthroughs and advances in treating Metastatic Breast Cancer @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Metastatic Breast Cancer Pipeline Outlook<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Metastatic Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Metastatic Breast Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Metastatic Breast Cancer pipeline landscape.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Breast Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Metastatic Breast Cancer (also known as stage IV) is breast cancer that has progressed to another region of the body, most often the liver, brain, bones, or lungs. The five-year Metastatic Breast Cancer survival rate is 22%, with a three-year median Metastatic Breast Cancer life expectancy. The Metastatic Breast Cancer symptoms vary widely depending on where the disease has spread. The most frequent Metastatic Breast Cancer sign that have gone to the bone is a sudden, noticeable new pain. Tumor biopsy is one of the most important tests for Metastatic Breast Cancer diagnosis.<\/p>\n<p style=\"text-align: justify;\">Systemic therapy, rather than surgery or radiation, is frequently used for Metastatic Breast Cancer treatment. Metastatic Breast Cancer treatment is intended to decrease tumors and limit their development, as well as relieve symptoms and enhance the quality of life. Metastatic Breast Cancer treatment may alter if one therapy stops functioning or the adverse effects become too bothersome.<\/p>\n<p style=\"text-align: justify;\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Find out more about immunotherapy for Metastatic Breast Cancer@&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Metastatic Breast Cancer Therapy<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>A snapshot of the Metastatic Breast Cancer Pipeline Drugs mentioned in the report:<\/strong><\/p>\n<table style=\"width: 624px;\" border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>Drugs<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Phase&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>MoA<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Disitamab Vedotin<\/p>\n<\/td>\n<td>\n<p>RemeGen<\/p>\n<\/td>\n<td>\n<p>Phase III<\/p>\n<\/td>\n<td>\n<p>Tubulin polymerization inhibitor<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>EndoTAG&reg;-1 (SB05)<\/p>\n<\/td>\n<td>\n<p>SynCore Biotechnology<\/p>\n<\/td>\n<td>\n<p>Phase III<\/p>\n<\/td>\n<td>\n<p>Proto-oncogene protein c-bcl-2 inhibitor<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>trastuzumab duocarmazine<\/p>\n<\/td>\n<td>\n<p>Byondis B.V.<\/p>\n<\/td>\n<td>\n<p>Phase III<\/p>\n<\/td>\n<td>\n<p>DNA inhibitor; ERBB 2 receptor antagonist<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>GNC 035<\/p>\n<\/td>\n<td>\n<p>Sichuan Baili Pharmaceutical Co., Ltd.<\/p>\n<\/td>\n<td>\n<p>Phase I<\/p>\n<\/td>\n<td>\n<p>Programmed cell death-1 ligand-1 inhibitor<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Stenoparib (2X-121)<\/p>\n<\/td>\n<td>\n<p>Allarity Therapeutics<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Poly(ADP-ribose) polymerase 1 and 2 inhibitor<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>HS-10342<\/p>\n<\/td>\n<td>\n<p>Jiangsu Hansoh Pharmaceutical Co., Ltd.<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Cyclin-dependent kinase 4 and 6 inhibitor<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>AND019<\/p>\n<\/td>\n<td>\n<p>Kind Pharmaceuticals LLC<\/p>\n<\/td>\n<td>\n<p>Phase I<\/p>\n<\/td>\n<td>\n<p>Selective estrogen receptor degrader<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>MRG002<\/p>\n<\/td>\n<td>\n<p>Shanghai Miracogen Inc.<\/p>\n<\/td>\n<td>\n<p>Phase II<\/p>\n<\/td>\n<td>\n<p>Tubulin polymerization inhibitor<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>DAN-222<\/p>\n<\/td>\n<td>\n<p>Dantari, Inc.<\/p>\n<\/td>\n<td>\n<p>Phase I<\/p>\n<\/td>\n<td>\n<p>DNA topoisomerase I inhibitor<\/p>\n<\/td>\n<td>\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>PMD-026<\/p>\n<\/td>\n<td>\n<p>Phoenix Molecular Designs<\/p>\n<\/td>\n<td>\n<p>Phase I<\/p>\n<\/td>\n<td>\n<p>Ribosomal protein S6 kinase inhibitor<\/p>\n<\/td>\n<td>\n<p>Oral<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Learn more about the novel and emerging Metastatic Breast Cancer pipeline therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Metastatic Breast Cancer Clinical Trials<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Breast Cancer Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The&nbsp;<strong>Metastatic Breast Cancer Pipeline<\/strong>&nbsp;report proffers an integral view of the Metastatic Breast Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Metastatic Breast Cancer Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Therapeutic Assessment By Product Type:&nbsp;<\/strong>Mono, Combination, Mono\/Combination<\/li>\n<li><strong>Therapeutic Assessment By Clinical Stages:&nbsp;<\/strong>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Route of Administration:&nbsp;<\/strong>Oral, Parenteral, Subcutaneous, Topical, Intravenous<\/li>\n<li><strong>Therapeutics Assessment<\/strong>&nbsp;<strong>By Molecule Type<\/strong>: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies<\/li>\n<li><strong>Key Metastatic Breast Cancer Companies<\/strong>: RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd.,&nbsp; Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.<\/li>\n<li><strong>Key Metastatic Breast Cancer Pipeline Therapies<\/strong>: Disitamab Vedotin, EndoTAG&reg;-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001,GNC-035, RGT-419B, Hemay022, SCR-6852, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Dive deep into rich insights into new Metastatic Breast Cancer drugs, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Metastatic Breast Cancer Treatment&nbsp;<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"1\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline: Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.1<\/p>\n<\/td>\n<td>\n<p>Disitamab Vedotin: RemeGen<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.2<\/p>\n<\/td>\n<td>\n<p>trastuzumab duocarmazine: Byondis B.V.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline: Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.1<\/p>\n<\/td>\n<td>\n<p>MRG002: Shanghai Miracogen Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline: Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.1<\/p>\n<\/td>\n<td>\n<p>DAN-222: Dantari, Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline: Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Metastatic Breast Cancer Pipeline Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Inactive Products in the Metastatic Breast Cancer Pipeline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>Key Companies in the Metastatic Breast Cancer Pipeline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Key Products in the Metastatic Breast Cancer Pipeline<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>For further information on the Metastatic Breast Cancer pipeline therapeutics, reach out @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Metastatic Breast Cancer Drugs<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-breast-cancer-pipeline-and-companies-analysis-report-2022-analysis-of-clinical-trials-landscape-therapies-route-of-administration-mechanism-of-action-and-developments-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-breast-cancer-pipeline-and-companies-analysis-report-2022-analysis-of-clinical-trials-landscape-therapies-route-of-administration-mechanism-of-action-and-developments-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Metastatic Breast Cancer Pipeline Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight DelveInsight&rsquo;s&nbsp;&#8216;Metastatic Breast Cancer Pipeline Insight 2022&#8217;&nbsp;report provides comprehensive global coverage of available, marketed, and pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-breast-cancer-pipeline-and-companies-analysis-report-2022-analysis-of-clinical-trials-landscape-therapies-route-of-administration-mechanism-of-action-and-developments-delveinsight_622199.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,447,405,406,413],"tags":[],"class_list":["post-622199","post","type-post","status-publish","format-standard","hentry","category-Business","category-Education","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/622199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=622199"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/622199\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=622199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=622199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=622199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}